In a twist, Amy­lyx's ALS drug will get a sec­ond crack at ad­comm en­dorse­ment af­ter FDA de­cides to re­con­vene ex­perts

Af­ter a close neg­a­tive vote ear­li­er this year, Amy­lyx Phar­ma­ceu­ti­cals will get an­oth­er at­tempt to per­suade FDA ad­vi­sors that its ex­per­i­men­tal ALS drug is ef­fec­tive.

US reg­u­la­tors will hold a sec­ond meet­ing of the Pe­riph­er­al and Cen­tral Ner­vous Sys­tem Drugs Ad­vi­so­ry Com­mit­tee to dis­cuss Amy­lyx’s ap­pli­ca­tion, the biotech an­nounced Tues­day morn­ing. The hear­ing, which will take place Sept. 7, will come less than six months af­ter the pre­vi­ous meet­ing end­ed in a 6-4 vote say­ing the com­pa­ny did not of­fer con­clu­sive proof its drug worked.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER